Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

A user visited a dermatologist for hair loss concerns and was prescribed a hair lotion called "Lotion revolotion evdermia," which is meant for hair toning, hydration, and anti-aging, not regrowth. The user found the dermatologist's behavior and the prescription to be questionable.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.

The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.

User "cheekykevin" shared 15-week progress using minoxidil and dermarolling, with positive results. Others suggested using ketoconazole for dandruff side effect.

The user shared their 9-month progress using topical finasteride and minoxidil, a Capillus laser cap, and a dermastamp for hair loss. They noted improvements and emphasized the importance of consistency for better results.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

People are discussing the potential benefits and drawbacks of a new time-release oral minoxidil (VDPHL01) for hair loss, with considerations about its cost, efficacy, and side effects compared to current treatments like 2.5mg doses and topical applications. Some users express interest in trying it if it proves effective and affordable, while others are cautious due to potential side effects or are satisfied with their current regimen.

The user noticed small circular hairless spots after a buzz cut and has been using finasteride, dutasteride, and oral minoxidil for hair loss. They are experiencing continuous shedding and thinning, and it is suggested they consult a dermatologist for a scalp examination and possible biopsy to determine if it's alopecia areata or androgenetic alopecia.

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

User experienced shedding and bald spots after 1 month of using Redensyl. Considering trying CosmeRNA as alternative treatment.

User noticed hair growth after 1.5 months using Fin, Min, stemoxydine, dermarolling, nizoral, and scalp massage. Others commented on promising results and potential improvement in 6 months.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The conversation discusses treating male pattern baldness with topical products containing Saw Palmetto extract. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user switched from liquid to foam minoxidil to reduce skin irritation but finds foam harder to apply effectively to the scalp. A suggestion was made to melt the foam into a liquid for easier application.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

Using a blunt tip syringe is an effective method for applying liquid topicals like minoxidil and RU58841, especially for those with thick or long hair experiencing diffuse thinning. The user found significant hair regrowth and increased density after using these topicals for less than three months.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation is about a user who started using finasteride to address crown balding, noticing reduced hair shedding and halted progression of male pattern baldness. The user also used a dermal stamp and expressed optimism about potential regrowth, despite a slight decrease in libido.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

Topical Minoxidil may cause pericardial effusion. Caution is advised when using Minoxidil, even topically.

The user has experienced limited hair regrowth using 1mg oral finasteride, topical minoxidil foam, and occasional dermarolling since August 2023. They are considering switching to dutasteride, adding oral minoxidil 2.5 mg, and RU58841 to improve results.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

The user experienced eyebrow hair loss and tried various treatments, including Minoxidil, a Capsaicin-based product, Latanoprost, Bimatoprost, Castor Oil, and Travoprost. Despite initial setbacks and a brutal shedding phase, they eventually saw positive results with Travoprost, encouraging others not to give up on treatments.

The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.